Back to Search
Start Over
Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations.
- Source :
-
Thoracic Cancer . Nov2022, Vol. 13 Issue 22, p3225-3228. 4p. - Publication Year :
- 2022
-
Abstract
- Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors are standard therapeutic agents for non‐small cell lung cancer (NSCLC) patients with major EGFR mutations such as exon 19 deletions and a L858R mutation, whereas treatment strategies for cases with uncommon EGFR mutations remain to be fully established. Here, we report a long‐term (≥20 years from initial diagnosis) NSCLC survivor carrying EGFR L858R and L747V mutations. The patient received gefitinib monotherapy, systemic chemotherapy/chemoimmunotherapy, and local consolidative therapies for oligometastatic lesions, and responded to afatinib rechallenge with a progression‐free survival of 12 months. The current case suggests that afatinib is effective in NSCLC patients with EGFR L858R and L747V mutations and that a therapeutic approach combining appropriately timed systemic therapies with local consolidative therapies for oligometastatic lesions improves long‐term survival. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17597706
- Volume :
- 13
- Issue :
- 22
- Database :
- Academic Search Index
- Journal :
- Thoracic Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 160233497
- Full Text :
- https://doi.org/10.1111/1759-7714.14678